drugset / Trial / NCT03717012

Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT03717012

Phase 4 Terminated 19 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

The main objectives of this study are: * Determine the difference in change from baseline in Six Minute Walk Distance (6MWD) when pulmonary rehabilitation (PR) is added to stable underlying nintedanib therapy in patients with idiopathic pulmonary fibrosis (IPF) * Determine the difference in change in Quality of Life (QoL) when pulmonary rehabilitation (PR) is added to stable underlying nintedanib therapy in patients with idiopathic pulmonary fibrosis (IPF) * Determine if there is an enduring effect in 6MWD, QoL and lung function from pulmonary rehabilitation (PR) when pulmonary rehabilitation (PR) is added to stable underlying nintedanib therapy in patients with idiopathic pulmonary fibrosis (IPF)

Timeline

Start
2018-11-15
Primary completion
2020-03-27
Completion
2020-06-10

Drugs

EvaluationDrugModalityDoseRoute
Background Nintedanib Small molecule